GHRELIN ANTAGONISM IN APPETITE AND ADIPOSITY

食欲和肥胖中的生长素释放肽拮抗作用

• 批准号: 7957922
• 负责人: RAUL A BASTARRACHEA
• 金额: $ 2.18万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-06 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7957922
• 关键词: Anti-Obesity Agents; Brain; Cardiovascular Diseases; Computer Retrieval of Information on Scientific Projects Database; Desire for food; Disease; Eating; Effectiveness; Energy Metabolism; Funding; Grant; Hormones; Human; Hypothalamic structure; Institution; Neurons; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Peripheral; Primates; Research; Research Personnel; Resources; Risk Factors; Source; Testing; United States National Institutes of Health; cancer type; ghrelin; improved; insulin sensitivity

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Obesity represents a major risk factor for diseases such as type 2 diabetes, cardiovascular disease and certain types of cancer. The hypothalamus in the brain is the central regulator of food intake and thus is a key target for anti-obesity drugs. Ghrelin is a peripheral hormone that acts on hypothalamic neurons to increase food intake. Human studies have shown that infusing ghrelin increases food intake and decreases energy expenditure. However, no human studies have been undertaken to test whether a ghrelin antagonist will have the opposite effects i.e. will decrease food intake. This proposal will evaluate the effectiveness of ghrelin antagonist in decreasing appetite and adiposity and improving insulin sensitivity.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 肥胖是 2 型糖尿病、心血管疾病和某些类型癌症等疾病的主要危险因素。大脑中的下丘脑是食物摄入的中枢调节器，因此是抗肥胖药物的关键靶点。生长素释放肽是一种外周激素，作用于下丘脑神经元以增加食物摄入量。人体研究表明，注射生长素释放肽可以增加食物摄入量并减少能量消耗。 然而，尚未进行人体研究来测试生长素释放肽拮抗剂是否会产生相反的作用，即减少食物摄入量。该提案将评估生长素释放肽拮抗剂在降低食欲和肥胖以及改善胰岛素敏感性方面的有效性。